Palladia is a new treatment for canine cancer that has been developed by Pfizer Animal Health. It is a prescription medication that belongs to a class of drugs called kinase inhibitors. Kinase inhibitors inhibit the activity of enzymes that regulate cell growth and division.

The drug is approved for use in dogs with relapsed or refractory mast cell tumors, which are a type of cancer that develops in certain cells called mast cells. These tumors can affect any part of your dog’s body, but they most often develop in the skin, lymph nodes, connective tissues, spleen, and gastrointestinal tract. The drug is also approved for use in dogs with multiple myeloma, which is another type of cancer affecting plasma cells (a type of white blood cell).

Published by AmberLDrake

Dr. Drake is an award-winning author and well-known cancer specialist in her field. She is best known for her extensive research on canine cancer prevention and nutrition, her dedication to help dogs live a long, happy life, and for teaching veterinary medicine. As the CEO of Canine Companions Co., the Founder of Drake Dog Cancer Foundation and Academy, and the Co-Founder of Preferable Pups, in addition to being a respected figure in the dog world, she has earned the respect of thousands of dog lovers worldwide.